The history of MF59® adjuvant: a phoenix that arose from the ashes
DT O'Hagan, GS Ott, GV Nest, R Rappuoli… - Expert review of …, 2013 - Taylor & Francis
The first clinical trial of an MF59®-adjuvanted influenza vaccine (Novartis) was conducted
20 years ago in 1992. The product that emerged (Fluad®, Novartis) was licensed first in Italy …
20 years ago in 1992. The product that emerged (Fluad®, Novartis) was licensed first in Italy …
Cell culture-based influenza vaccines: A necessary and indispensable investment for the future
NR Hegde - Human vaccines & immunotherapeutics, 2015 - Taylor & Francis
The traditional platform of using embryonated chicken eggs for the production of influenza
vaccines has several drawbacks including the inability to meet the volume of required doses …
vaccines has several drawbacks including the inability to meet the volume of required doses …
Deep phenotyping of the unselected COPSAC2010 birth cohort study
H Bisgaard, NH Vissing, CG Carson… - Clinical & …, 2013 - Wiley Online Library
Background We hypothesize that perinatal exposures, in particular the human microbiome
and maternal nutrition during pregnancy, interact with the genetic predisposition to cause an …
and maternal nutrition during pregnancy, interact with the genetic predisposition to cause an …
An overview of adjuvant formulations and delivery systems
A García, JB De Sanctis - Apmis, 2014 - Wiley Online Library
Adjuvants may promote immune responses: by recruiting professional antigen‐presenting
cells (APC s) to the vaccination site, increasing the delivery of antigens to APC s, or by …
cells (APC s) to the vaccination site, increasing the delivery of antigens to APC s, or by …
[HTML][HTML] Next-generation influenza HA immunogens and adjuvants in pursuit of a broadly protective vaccine
KA Nagashima, JJ Mousa - Viruses, 2021 - mdpi.com
Influenza virus, a highly mutable respiratory pathogen, causes significant disease nearly
every year. Current vaccines are designed to protect against circulating influenza strains of a …
every year. Current vaccines are designed to protect against circulating influenza strains of a …
[HTML][HTML] Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: a systematic review and meta …
J Yang, J Zhang, T Han, C Liu, X Li, L Yan, B Yang… - Medicine, 2020 - journals.lww.com
Background: Influenza is a severe disease burden among all age groups. This study aimed
to review the efficacy of inactivated influenza vaccines with MF59 adjuvant and non …
to review the efficacy of inactivated influenza vaccines with MF59 adjuvant and non …
[HTML][HTML] Altered response to A (H1N1) pnd09 vaccination in pregnant women: a single blinded randomized controlled trial
AL Bischoff, NV Følsgaard, CG Carson, J Stokholm… - Plos one, 2013 - journals.plos.org
Background Pregnant women were suspected to be at particular risk when H1N1pnd09
influenza became pandemic in 2009. Our primary objective was to compare the immune …
influenza became pandemic in 2009. Our primary objective was to compare the immune …
[HTML][HTML] Antibody persistence in adults two years after vaccination with an H1N1 2009 pandemic influenza virus-like particle vaccine
N Valero-Pacheco, M Pérez-Toledo… - PLoS …, 2016 - journals.plos.org
The influenza virus is a human pathogen that causes epidemics every year, as well as
potential pandemic outbreaks, as occurred in 2009. Vaccination has proven to be sufficient …
potential pandemic outbreaks, as occurred in 2009. Vaccination has proven to be sufficient …
[HTML][HTML] Immunogenicity of influenza vaccines: evidence for differential effect of secondary vaccination on humoral and cellular immunity
SK Rosendahl Huber, M Hendriks, RHJ Jacobi… - Frontiers in …, 2019 - frontiersin.org
While currently used influenza vaccines are designed to induce neutralizing antibodies, little
is known on T cell responses induced by these vaccines. The 2009 pandemic provided us …
is known on T cell responses induced by these vaccines. The 2009 pandemic provided us …
An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A (H1N1) pdm09 vaccines
MI Hauser, DJ Muscatello, ACY Soh, DE Dwyer… - Vaccine, 2019 - Elsevier
Background Although oil-in-water adjuvants improve pandemic influenza vaccine efficacy,
AS03 versus MF59 adjuvant comparisons in A (H1N1) pdm09 pandemic vaccines are …
AS03 versus MF59 adjuvant comparisons in A (H1N1) pdm09 pandemic vaccines are …